Drug Trial Radar · NCT02365532
Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults
Last checked: Nov 20, 2026Latest source record: May 20, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Feb 2015
Primary completion
May 2015
Study completion May 2015
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Feb 19, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will evaluate the effect of oral GS-6615 on QTc interval in healthy adults with dofetilide-induced QTc prolongation.
Conditions
- Long QT Syndrome
Interventions
GS-6615Drug
GS-6615 tablets administered orally
Placebo to match GS-6615Drug
Placebo to match GS-6615 tablets administered orally
Placebo to match dofetilideDrug
Placebo to match dofetilide capsules administered orally
DofetilideDrug
Dofetilide 500 μg capsules administered orally according to the current prescribing information
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in daytime QT interval corrected for heart rate using the Fridericia formula (QTcF)Time frame: Up to 6 days
- Pharmacokinetic (PK) profiles of GS-6615 and dofetilideTime frame: Predose and postdose on Days -2 through Day 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Spaulding Clinical Research, LLC
West Bend, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.